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Abstract 
The combretastatins are an important class of tubulin-binding agents. Of this family, a 
number of compounds are potent tumor Vascular Disrupting Agents (VDAs) and have shown 
promise in the clinic for cancer therapy. We have developed a modular synthetic route to 
combretastatin analogs based on a pyrazole core through highly-regioselective alkyne 
cycloaddition reactions of sydnones. These compounds show modest to high potency against 
human umbilical vein endothelial cell proliferation. Moreover, evidence is presented that 
these novel VDAs have the same mode of action as CA4P and bind reversibly to E-tubulin ± 
believed to be a key feature in avoiding toxicity. The most active compound from in vitro 
studies was taken forward to an in vivo model and instigated an increase in tumor cell 
necrosis. 
Introduction 
Tumor growth and metastasis are dependent upon a functional blood vessel network1 and, 
since tumor blood vessels are abnormal, they represent an attractive target for cancer 
therapy.2,3 Tumor Vascular Disrupting Agents (VDAs) cause a rapid and selective collapse of 
tumor blood vessels leading to widespread tumor cell death via necrosis.4 The most well-
studied class of VDAs are the tubulin binding microtubule depolymerizing agents. The tumor 
vascular disrupting properties of colchicine, the classic tubulin binding agent of this type, 
have been known since the 1930s, but these effects are only seen at near to the maximum 
tolerated dose (MTD) in mice.5,6 The structurally related stilbene compounds, the 
combretastatins, were isolated from the Cape Bush Willow tree, Combretum caffrum in the 
late 1980s.7 These compounds were initially studied for their potential as antimitotic agents.8 
However, it later became apparent that the combretastatins had great potential as VDAs.9 The 
lead compound, combretastatin A-4 (CA4), was shown to be effective at causing selective 
tumor vascular collapse, within minutes, at non-toxic doses.10 It was swiftly developed into 
the water-soluble, sodium phosphate salt prodrug, disodium combretastatin A-4 3-O-
phosphate (CA4P).11 CA4P is not active as a tubulin binding agent, but is rapidly cleaved in 
plasma to CA4.12 The lower toxicity (and thus higher MTD) of CA4 compared to colchicine 
LVDWWULEXWHGWR&$ELQGLQJUHYHUVLEO\WRWKHȕ-tubulin subunit, as opposed to colchicine that 
binds pseudo-irreversibly.13 CA4P is currently undergoing Phase II/III clinical trials in 
combination with bevacizumab.14 
Although CA4P is a promising clinical candidate, it does have a number of issues associated 
with it. Firstly, the cis orientation of the olefinic linker is key to activity, with the trans 
isomer being essentially inactive15 ± an issue further emphasized by the tendency of cis 
stilbenes to undergo cis-trans isomerization in heat, light and protic media.16 A promising 
strategy to overcome this issue has been the incorporation of heterocyclic motifs to replace 
the olefinic linker.17,18,19,20,21,22,23 This strategy allows the cis configuration of the 
FRPEUHWDVWDWLQVWREH³IL[HG´LQKLELWLQJPHWDEROLFGHFRPSRVLWLRQFigure 1). However, any 
compound design would have to take into account the result of molecular docking studies that 
clearly indicate the need for appropriately disposed electron rich aryl rings, such as those in 
colchicine and CA4, which are key pharmacophores for tubulin polymerization 
inhibition.24,25,26 
 Figure 1. Tubulin-binding VDAs 
Although a number of significant contributions have been made in the field of rigid 
combretastatin analogs, only limited examples of this approach using a pyrazole core have 
been documented.16,20,27,28 To the best of our knowledge, there are no examples of simple 
(without extra substitution of the pyrazole core), pyrazole-bridged CA4 analogs reported and 
there has not been a systematic evaluation into the effect of substitution pattern. The pyrazole 
motif is an important fragment in the pharmaceutical industry and is present in a number of 
commercial medicines and agrichemicals.29,30 However, synthetic routes to these structurally 
important diazoles are often linear or suffer from regioselectivity issues during the 
heterocycle forming step. In this regard, we felt that sydnones could represent convenient and 
potentially versatile starting materials to access these desirable therapeutic analogs. Sydnones 
belong to the mesoionic family of compounds and they undergo [3+2] cycloaddition-
retrocycloaddition reactions with alkynes to form pyrazoles.31 These cycloadditions can be 
highly regioselective and offer access to a wide range of pyrazoles.32,33,34,35,36,37 In the context 
of developing novel VDAs, we envisaged that the sydnone cycloaddition strategy could be 
exploited to access a broad range of pyrazole templated combretastatin analogs from similar 
starting materials (Scheme 1). However, we recognized that a number of synthetic challenges 
needed to be met in order to achieve this goal: (1) access to 1,5-substituted pyrazoles 
theoretically required high temperature cycloaddition with acetylene gas; (2) 4,5-disubstituted 
pyrazoles required the innate regioselectivity of the cycloaddition with terminal alkynes to be 
reversed (typically, the largest substituent is incorporated at the C3); (3) the cycloaddition of 
biaryl alkynes for the preparation of 3,4-substituted pyrazoles was unlikely to proceed with 
regiocontrol, thereby delivering isomeric mixtures. 
 
Scheme 1. Sydnone cycloaddition strategy to pyrazole-based analogs 
Results and Discussion 
Preparation of 1,5-Disubstituted Analogs   
Our investigations began with the preparation of 1,5-disubstituted pyrazoles. We proposed a 
strategy that exploited our previously developed direct arylation of sydnones to furnish the 
key diaryl intermediates (Scheme 2).38 We then envisaged that trimethylsilylacetylene could 
act as a high-boiling point acetylene equivalent in the cycloaddition to provide the target 
pyrazoles after protodesilylation. 
 
Scheme 2. Strategy for the synthesis of 1,5-disubstituted pyrazoles 
Sydnone starting materials were readily prepared by established routes of N-nitrosation of 
amino acids, followed by cyclodehydration with trifluoroacetic anhydride (TFAA).31,38 The 
synthesis began with the coupling of sydnone 1 affording diaryl sydnone 2 in moderate yield 
(Scheme 3). Pleasingly, sydnone 2 underwent successful cycloaddition with 
trimethylsilylacetylene to afford TMS-substituted pyrazoles 3a and 3b in good yield and 
excellent (but inconsequential) regioselectivity. Previous experience had suggested that 3-
silyl pyrazoles could be particularly resistant to hydrolysis. Fortunately however, a refluxing 
solution of TBAF in THF afforded the desilated product 4 in useful yield. Finally, simple 
hydrogenation of the benzyl ether afforded CA4 analog 5. 
 
Scheme 3. Synthesis of pyrazole 5 
Preparation of the isomeric 1,5-pyrazole 10 required a slight modification to the route. 
Sydnone 6 was subjected to direct arylation conditions, followed by benzyl protection of the 
phenol (Scheme 4). Surprisingly, benzyl protection of the phenol prior to direct arylation 
resulted in a sydnone that decomposed when subjected to various direct arylation conditions. 
Sydnone 7 underwent cycloaddition in very good yield and regioselectivity. TBAF 
deprotection of the trimethylsilyl group proceeded in moderate yield. The resulting pyrazole 
9 was contaminated with a small amount of an inseparable, unknown by-product. 
Fortunately, analog 10 was isolated cleanly after benzyl hydrogenation. 
 
Scheme 4. Synthesis of pyrazole 10 
Preparation of 4,5-Disubstituted Analogs 
We next turned our attention to the preparation of 4,5-disubstituted pyrazoles. Elegant work 
by Taran et al. demonstrated that copper catalysis can reverse the natural regioselectivity of 
sydnone cycloadditions.33 Recently, the chemistry has been improved to tolerate bromide 
substituents at the sydnone C4 position, which could then be further elaborated by cross-
coupling.32 However, this chemistry is currently limited to N-aryl sydnones. As our interest 
lay with N-alkyl sydnones, a new methodology was needed. We proposed to extend the 
strategy used for the synthesis of 1,5-substituted pyrazoles to borylated 
trimethylsilylacetylene (Scheme 5). We have previously reported the cycloaddition of 
alkynylboranes with sydnones to be highly regioselective and importantly, tolerant of N-
alkylsydnones.35 In the case of disubstituted alkynes, the boron substituent is generally 
incorporated at the pyrazole C4 position. 
 Scheme 5. Strategy for the synthesis of 4,5-disubstituted pyrazoles 
The synthesis began with the direct arylation of N-methyl- and N-benzylsydnone, which 
proceeded smoothly on gram scale affording C4-arylated sydnones 11-14 (Scheme 6). We 
were delighted to find all substrates successfully underwent cycloaddition and the 
corresponding pyrazoles were isolated as single regioisomers, 15-18, albeit contaminated 
with varying amounts of protodeborylated by-product. The Suzuki-Miyaura reaction required 
VRPHRSWLPL]DWLRQEXWZDVVXFFHVVIXOO\DFKLHYHGXVLQJ%XFKZDOG¶V;3KRV3G*SUHFDWDO\VW
to afford 19-22. The products were again contaminated with varying amounts of 
protodeborylated by-product. Pleasingly, subjection of 23-26 to refluxing TBAF successfully 
resulted in silyl deprotection, and 23-26 were readily separable from their corresponding by-
products at this stage. Benzyl hydrogenation afforded the 4,5-disubstituted analogs of CA4, 
27-32. In the case of N-benzylpyrazoles 24 and 26, incomplete hydrogenation afforded a 
separable mixtures of N-H pyrazoles 28 and 31 and N-benzylpyrazoles 29 and 32 
respectively. 
 Scheme 6. Synthesis of 4,5-disubstituted analogs 
Preparation of 3,4-Disubstituted Analogs 
The final analogs to prepare were the 3,4-disubstituted pyrazoles. It was originally anticipated 
that we could utilize alkynylboronate cycloaddition chemistry to access these compounds 
(Scheme 7, A).36 However, we found that alkynes bearing these particularly electron rich 
aromatic rings were prone to protodeborylation, and pyrazole boronic esters could not be 
obtained under a variety of conditions. We proposed an alternative route whereby the innate 
regioselectivity of the sydnone cycloaddition was exploited, followed by bromination and 
subsequent cross-coupling (Scheme 7, B). 
 Scheme 7. Strategy for the synthesis of 3,4-disubstituted pyrazoles 
The route began with the cycloaddition of N-methyl and N-benzylsydnone with 
arylacetylenes. The reactions proceeded in good yield and high regioselectivity to afford 
pyrazoles 33-36 (Scheme 8). We were pleased to find that N-bromosuccinamide (NBS) in 
acetonitrile rapidly and selectively brominated the pyrazoles. After basic work-up, the 
brominated products could be subjected without further purification to Suzuki-Miyaura 
coupling, affording products 37 and 39 in good yield over 2 steps. Products 38 and 40 were 
isolated after subjection of the crude Suzuki-Miyaura products to silyl deprotection 
conditions of potassium carbonate in refluxing methanol in useful yield over 3 steps. In the 
case of N-methyl analogs 37 and 39, this route represents rapid access to the compounds in 
effectively 2 pots. Compounds 38 and 40 were subjected to hydrogenation to afford the free 
NH-pyrazole analogs 28 and 31, thus providing an alternative, shorter route to these analogs 
from the alkynylboronate strategy above. 
 Scheme 8. Synthesis of 3,4-disubstituted analogs 
Biological Evaluation 
With a library of twelve pyrazole-based analogs of CA4 in hand, attention turned to 
evaluating their potential as anticancer agents. Studies within our laboratories have 
previously shown that for CA4P, vascular disruptive effects dominate rather than direct 
targeting of cancerous cells.39 Therefore, we proposed that the primary target of VDAs, 
endothelial cells, would provide an accurate insight into the activity of the pyrazole-based 
analogs.  
Initial Screens 
CA4 is a tubulin binding agent, therefore we proposed that a convenient method for the rapid 
assessment of activity was to study the effects of compounds on endothelial cell proliferation, 
which is inhibited by disruption of the microtubule-rich mitotic spindle. It is important to 
note that the action of CA4 as a VDA is not due to effects on HUVEC proliferation or 
prevention of mitotic spindle formation. However, the analysis of drug-induced effects cell 
proliferation   provide a useful insight into microtubule targeting potential. Screening results 
are depicted in Table 1. 
 
Entry Compound R1 R2 R3 R4 GI50 
1 5 Ar1 Ar2 H H 28 nM   
2 10 Ar2 Ar1 H H >750 nM 
3 27 Me Ar1 Ar2 H 68 nM 
4 28 H Ar1 Ar2 H >5000 nM 
5 29 Bn Ar1 Ar2 H >2500 nM 
6 30 Me Ar2 Ar1 H 118 nM 
7 31 H Ar2 Ar1 H 7 nM 
8 32 Bn Ar2 Ar1 H >750 nM 
9 37 Me H Ar2 Ar1 >5000 nM 
10 38 Bn H Ar2 Ar1 >5000 nM 
11 39 Me H Ar1 Ar2 256 nM 
12 40 Bn H Ar1 Ar2 >2000 nM 
13 CA4P - - - - 8  nM 
14 Colchicine - - - - 25  nM 
Table 1. Values for growth inhibition of HUVECs by pyrazole anologs vs. CA4P and 
colchicine 
The variation observed in the activities of the compounds was quite remarkable given that all 
of the compounds screened were direct analogs of CA4, differing only in their location on the 
pyrazole core. The most active compounds 5, 27, 30 and 31 (entries 1, 3, 6 and 7) exhibited 
low nanomolar activity. The most active compound 31, showed similar activity to CA4P 
(entry 7 vs 13). However, a number of compounds only showed low micromolar activities 
(entries 4, 9 and 12). Further studies were undertaken on the two most active compounds 5 
and 31 (Figure 2). 
Immunofluorescence Studies 
To confirm that the drug effects were due to microtubule disruption, drug-induced changes in 
the endothelial cell cytoskeleton and morphology were studied via immunofluorescence for 
compounds 5 and 31. The microtubule disruption associated with CA4P treatment is also 
accompanied by changes in cell shape and morphology brought about by the rapid 
remodelling of the actin cytoskeleton.40 Therefore, endothelial cells in culture were stained 
for actin filaments using phalloidin, microtubules using an antibody to Etubulin and nuclei 
stained with 4',6-diamidino-2-phenylindole (DAPI). 
In cells that are in interphase, polymers of Dtubulin and Etubulin originate from the 
centrosome and radiate to the edge of the cell as tubular filaments referred to as microtubules 
(Figure 3, A), whereas actin is mostly pericellular (Figure 3, B). Upon treatment with 250 nM 
CA4P for 30 minutes, interphase microtubules became disrupted (Figure 3, C), leading to 
changes in cell morphology. Disruption of microtubules led to the formation of actin stress 
fibres across the cells (Figure 3, D). Interestingly, a longer (90 minutes) treatment at a higher 
dose of 1 PM was required for similar effects to be observed with colchicine (Figure 3, E and 
F). A 250 nM treatment with 5 resulted in the disruption of interphase microtubules and 
significant changes in endothelial cell shape and morphology (Figure 3, G and H). Similarly, 
a 250 nM treatment with 31 also caused pronounced effects on endothelial cell shape and 
morphology (Figure 3, I and J). 
 Figure 3. Drug effects on HUVEC cytoskeletal structures. Cells were treated with a single 
dose of either vehicle (A, B), 250 nM CA4P (C, D), 1 PM colchicine (E, F), 250 nM drug 5 
(G, H) or 250 nM drug 31 (I, J). Drug treatments were for 30 min with CA4P, drug 5 and 
drug 31 and 90 minutes with colchicine. Cells were fixed and stained with an antibody to E-
tubulin (A, C, E, G, I) and F-actin (B, D, F, H, J) and nuclei stained with DAPI. 
Recovery Experiments 
CA4P is thought to be a potent VDA at well below its maximum tolerated dose due to the 
reversibility of its binding to tubulin.12 Therefore, we tested the reversibility of the tubulin 
binding of compounds 5 and 31 using immunofluorescence in parallel with CA4P and 
colchicine.  
As shown in Figure 3, a 30 minute treatment with 250 nM of either CA4P, 5 or 31 was 
sufficient to produce a profound effect on cellular morphology. A 30 minute treatment with 
CA4P, followed by removal of the drug and 60 minutes incubation led to significant recovery 
of the cells (Figure 4, A and B). There was a clear recovery of microtubules and a reduction 
in actin stress fibres. Importantly, cells treated with colchicine did not show signs of recovery 
within the same time frame (Figure 4, C and D). Indeed, recovery was not observed, even 
after a 120 minute incubation upon removal of the drug (Figure 4, E and F). Our 
interpretation of these data is as follows. Firstly, that the binding of colchicine was indeed 
pseudo-irreversible whereas CA4 bound reversibly, and secondly that its action was slower 
than that of CA4. It is also interesting to note that this slower action was not due to a 
decreased rate of diffusion through the cell membrane. If it were the case, removal of the 
drug after thirty minutes would prevent microtubule disruption. Furthermore, 5 appeared to 
have a similar profile to CA4P with the cells also showing full recovery after 60 minutes 
(Figure 4, G and H). Intriguingly, cells treated with 31 did not recover significantly 60 
minutes after drug removal (Figure 4, I and J). However, early signs of recovery were 
apparent at this time point, because microtubules were beginning to radiate from the 
centrosome (I). Full recovery of the cytoskeleton was nevertheless seen 120 minutes after 
drug removal (Figure 4, K and L). This slower recovery than CA4P was particularly 
interesting because we felt it could be an indicator to either a wider therapeutic window or 
toxicity. Either result would add value to this assay in assessing the viability of compounds as 
VDAs in vitro. Such a model has been quite elusive thus far. Therefore, we sought to further 
probe the potential of 31 as a VDA. 
 
Figure 4. Recovery of cytoskeletal structures after drug removal.  HUVECs were treated 
with a single dose of either 250 nM CA4P (A, B), 1 PM colchicine (C, D, E, F), 250 nM drug 
5 (G, H) or 250 nM drug 31 (I, J, K, L). Drug treatments were for 30 min. Cells were then 
washed with serum containing medium and allowed to recover for 60 min (A, B, C, D, G, H, 
I, J) or 120 min (E, F, K, L). Cells were fixed and stained with an antibody to E-tubulin (A, 
C, E, G, I, K) and F-actin (B, D, F, H, J, L) and nuclei stained with DAPI. 
Analysis of Rho-GTPase/Rho Kinase Signalling Pathway Activation. 
We focused on the most active compound from the initial screens, 31 and compared its 
activity to CA4P in assays linked to mode of action and vascular disruption. Previous studies 
had revealed that activation of the RhoA-GTPase signal pathway was involved in actin 
remodelling and monolayer disruption caused by CA4P.40,41 Activated Rho-GTPase causes 
contractility and stress fibre formation through polymerization of actin and the 
phosphorylation of myosin light chain (MLC). The latter activity is dictated through the 
activation of serine/threonine Rho kinases (ROCKs). Thus, we investigated both 31 and 
CA4P induced effects on the phosphorylation of MLC (pMLC) in HUVECs. As shown in 
Figure 5, both compounds instigated significant increases in pMLC over a range of 
concentrations, indicating that both compounds were acting via a similar pathway. 
Compound 31 induced significant phosphorylation of MLC at the lower tested concentration 
of 50 nM while CA4P was less active at this dose. To further confirm the involvement of 
ROCK in the induction of MLC phosphorylation by compound 31, cells were treated with the 
specific ROCK inhibitor Y-27632. Similar to what was previously published for CA4P,40,41 
the induction of MLC phosphorylation by compound 31 was abrogated by Y-27632, 
confirming the involvement of ROCK in this process (Figure 5C). 
 Figure 5. Drug-induced induction of phosphorylation of Rho kinase target MLC. HUVECs 
were treated with increasing concentrations of CA4P or drug 31 for 15 minutes after which 
proteins were extracted and analyzed for phosphorylation of ROCK target MLC (pMLC) by 
western blotting using an antibody specific to the phosphorylated form of the protein (A). 
Immunoblots were reprobed with an antibody to actin to confirm equal loading.  In B, pMLC 
band intensities were analyzed by ImageJ and results expressed as fold-change over control 
cells treated with vehicle alone. Each column represents the mean of 3-4 independent cell 
culture experiments±SEM. * represents P < 0.05 for the significance of differences between 
drug treatment groups and controls (one-way ANOVA followed by a Tukey post-test). In C, 
HUVECs were incubated with Rho kinase inhibitor Y-27632 (5 PM) for 5 minutes and then 
treated with 500 nM drug 31 for 15 minutes. Proteins were extracted and analyzed for pMLC 
as in A. 
Endothelial Monolayer Permeability Experiments 
Rapid disruption of the endothelial cell monolayer is key to the activity of VDAs.40 
Therefore, studies on the effects of compound 31 and CA4P on cell monolayer permeability 
to fluorescent dextran were undertaken. Confluent HUVEC monolayers were treated for 30 
minutes before removal of the drug and addition of fluorescent dextran for a further 30 
minutes. Since 31 was shown above to be effective at triggering induction of Rho signalling 
at a concentration of 50 nM (see Figure 5), both CA4P and compound 31 were tested at this 
dose. Both drugs instigated a significant increase in monolayer permeability at this low dose 
(Figure 6). Importantly however, 31 led to a significantly larger increase in monolayer 
permeability than CA4P at this dose. This correlated with the increased activity of compound 
31 over CA4P in stimulating pMLC phosphorylation. 
 
Figure 6. Drug-induced changes in endothelial monolayer permeability comparing CA4P and 
31. Confluent monolayers of cells grown on microporous filter inserts were treated with 
vehicle control, CA4P (50 nM, 30 min) or compound 31 (50 nM, 30 min).  Drugs were 
removed and replaced with FITC±dextran for a further 30 min. The passage of FITC-dextran 
through the monolayer was quantified and expressed as a percentage of FITC that passed 
through a filter without cells. Results are a mean of 3 independent experiments ± SEM. ** 
represents P < 0.01 and *** represents P < 0.001 for the significance of differences between 
groups (one-way ANOVA followed by a Tukey post-test). 
In Vivo Studies 
The maximum tolerated dose (MTD) of 31 in SCID (severe combined immunodeficiency) 
mice was found to be greater than 162 mg/kg (0.454 mmol/kg; data not shown). We next 
investigated whether 31 showed efficacy in a tumor model. SCID mice were implanted with 
5 x 106 SW1222 (human colorectal adenocarcinoma) cells via subcutaneous injection. Tumors 
were allowed to reach 8 mm in diameter and then treated with either vehicle (50% 
Na2CO3/NaCl), CA4P (100 mg/kg, 0.227 mmol/kg) or a solution of 31 (81 mg/kg, 0.227 
mmol/kg). Tumors were excised 24 hours later and necrosis levels calculated in H&E stained 
 P WKLFN VHFWLRQV E\ D UDQGRP SRLQW VFRULQJ PLFURVFRS\ PHWKRG XVLQJ D µ&KDONOH\¶
eyepiece graticule.42,43 As shown in Figure 7, CA4P treated tumors were significantly more 
necrotic than the untreated tumors, with % necrosis very similar for CA4P and 31 treated 
tumors. However, the tendency for necrosis to increase with 31 treatment just failed to reach 
significance with the animal numbers used (Figure 7). CA4P appeared to exhibit greater 
variability in necrosis levels with some tumors showing no response upon treatment. 
Maximum response was higher for CA4P, but over one third of the treatment group failed to 
respond. In contrast, treatment with 31 resulted in much less variation, with 11% (a single 
tumor) failing to respond. It is of particular note that 31 showed signs of efficacy in vivo 
without further derivatisation for water solubility and appeared to remain active in the 
circulation. 
 Figure 7. In vivo study of drug-induced effects on tumor cell necrosis comparing CA4P and 
31. Each point represents the combined data from a single tumor. 5 sections (cut at different 
tumor depths) were analyzed per tumor using a x20 objective on a Nikon Eclipse TS100 
microscope microscope.  The total section was analyzed and % necrosis calculated in each 
field from the relative number of points in a Chalkley eyepiece graticule co-incident with 
necrotic versus viable tumor tissue. Bars represent the mean±SEM of the combined data for 
each tumor. * represents P < 0.05 for the significance of differences between groups (one-
way ANOVA followed by a Tukey post-test). 
Conclusion 
In conclusion, we have successfully utilized highly-regioselective cycloadditions of sydnones 
to access twelve direct pyrazole-based analogs of combretastatin A4. Two of the compounds 
display similar efficacy to CA4P in vitro. We have established that both compounds exhibit 
reversible binding and that the most active compound activates the RhoA-ROCK pathway, a 
characteristic of a CA4P-like mode of action. The most active compound also significantly 
increases cell monolayer permeability relative to CA4P at doses of 50 nM. Finally, evaluation 
of compound efficacy in vivo showed a tendency toward increased necrosis in a similar 
manner to CA4P at an equivalent dose, without the need for the incorporation of water 
solubilizing groups. 
Experimental 
1H NMR spectra were recorded on a Bruker AVIII HD 400 (400 MHz), Bruker AVI 400 (400 
MHz), or DPX-400 (400 MHz) supported by an Aspect 3000 data system. Chemical shifts are 
reported in parts per million (ppm) from tetramethylsilane with the residual protic solvent 
resonance as the internal standard (CHCl3: G7.26DMSO: G 2.50). 13C NMR spectra were 
recorded on a Bruker AVIII HD 400 (100.6 MHz), Bruker AVI 400 (100.6 MHz), or DPX-
400 (100.6 MHz) with complete proton decoupling. Chemical shifts are reported in ppm from 
tetramethylsilane with the solvent as the internal reference (CDCl3: G77.16, DMSO: 
G39.52). High-resolution mass spectra (HRMS), recorded for accurate mass analysis, were 
performed on electrospray mode (TOF ES+). Infrared (IR) spectra were recorded on a Perkin 
Elmer Paragon 100 FTIR spectrophotometer, Qmax in cm-1. Samples were recorded as solids 
using a solid probe. Bands were characterised as broad (br), strong (s), medium (m), and 
weak (w). All solvents and reagents obtained from Acros, Fisher, Sigma, Alfa or Fluorochem 
and used without purification unless specified. Flash chromatography was performed on 
silica gel (BDH Silica Gel 60 43-60). Thin layer chromatography (TLC) was performed on 
aluminium backed plates pre-coated with silica (0.2 mm, Merck DC-alufolien Kieselgel 60 
F254) which were developed using ultraviolet (UV). HPLC chromatograms were obtained on 
a Perkin Elmer Series 200 HPLC system using a Waters XBridge C18 250 x 4.6 mm column 
and a gradient of 5-95% MeCN/H2O over 20 min. All compounds submitted for biological 
testing were recrystallized to consistent melting point and judged as >95% pure by HPLC and 
1H and 13C NMR spectroscopy. 
N-Methyl-, N-benzyl- and N-(3,4,5-trimethoxyphenyl)sydnone (1)38 were prepared by 
standard methods (cyclodehydration of N-nitroso amino acid with trifluoroacetic anhydride) 
similarly to N-(3-hydroxy-4-methoxyphenyl)sydnone (see below).  
General Procedure A: Direct Arylation of Sydnones. A mixture of sydnone (1 eq.), aryl 
halide (1.5 eq.), palladium acetate (5 mol %), XPhos (10 mol %) and potassium carbonate (2-
3 eq.) in DMF (0.1 ± 0.5 M) under an atmosphere of nitrogen was heated at 80 - 120 qC for 
14 hours before the reaction was allowed to cool to ambient temperature and water was 
added. The resulting mixture was extracted with ethyl acetate:40-60 petroleum ether (9:1) 
and the combined organic layers dried over MgSO4 and concentrated in vacuo. Flash silica 
chromatography (eluting solvent 20%-100% ethyl acetate in 40-60 petroleum ether) afforded 
the target 3,4-disubstituted sydnones. The compounds could be further purified by 
recrystallization from ethanol or dichloromethane/petrol. 
General Procedure B: Cycloaddition of Sydnones with Terminal Alkynes.  
A Schlenk tube was charged with sydnone (1 eq.), alkyne (2-4 eq.) and xylenes (1 M). The 
tube was then sealed and heated at 160 RC for 24 hours. The mixture was allowed to cool to 
ambient temperature and loaded onto a short plug of silica and washed with 40-60 petroleum 
ether before elution with ethyl acetate. Volatiles were removed in vacuo and the crude 
residue purified by flash silica chromatography (gradient starting with 100% 40-60 petroleum 
ether and ending with 40% ethyl acetate in 40-60 petroleum ether) affording the target 
trisubstituted pyrazoles as mixtures of regioisomers. Only characterization for the major 
regioisomer is reported. 
General Procedure C: Preparation of Pyrazole Boronic Esters. A Schlenk tube was 
charged with sydnone (1 eq.), alkyne (2 eq.) and xylenes (1 M). The tube was then sealed and 
heated at 180 RC for 48 hours. The mixture was allowed to cool to ambient temperature and 
loaded onto a short plug of silica and washed with 40-60 petroleum ether before elution with 
ethyl acetate. Volatiles were removed in vacuo and the crude residue purified by flash silica 
chromatography (gradient starting with 100% 40-60 petroleum ether and ending with 40% 
ethyl acetate in 40-60 petroleum ether) affording the target pyrazole boronic esters as an 
inseparable mixture of the target material and the product arising from protodeboronation. 
Only characterization for the target material is reported. 13C NMR signals for C-B were not 
observed due to T2 broadening. 
General Procedure D: Suzuki-Miyaura Coupling of Pyrazole Boronic Esters. A flask 
equipped with a reflux condenser was charged with pyrazole boronic ester (1 eq.), 
XPhosPdG2 (0.1 eq.), sodium carbonate (2 eq.) and degassed 1,2-dimethoxyethane:water 
(1:1, 0.1 M) and heated at 80 RC under an inert atmosphere of nitrogen for 14 hours. The 
mixture was allowed to cool to ambient temperature, poured into water and extracted with 
ethyl acetate. The combined organic layers were dried over MgSO4 and concentrated in 
vacuo. Flash silica chromatography (gradient starting with 100% 40-60 petroleum ether and 
ending with 40% ethyl acetate in 40-60 petroleum ether) afforded the target cross-coupled 
pyrazoles as an inseparable mixture of the target material and the product arising from 
protodeboronation. Only characterization for the target material is reported. 
General Procedure E: Trimethylsilyl Group Cleavage. A flask equipped with a reflux 
condenser was charged with pyrazole (1 eq.), and TBAF (10 eq. 1 M solution in THF) and 
heated at reflux under an inert atmosphere of nitrogen for 24 hours. The mixture was allowed 
to cool to ambient temperature, poured into water, neutralized with NaHCO3 and extracted 
with ethyl acetate. The combined organic layers were dried over MgSO4 and concentrated in 
vacuo. Flash silica chromatography (gradient starting with 100% 40-60 petroleum ether and 
ending with 60% ethyl acetate in 40-60 petroleum ether) afforded the target desilated 
pyrazoles. 
General Procedure F: Bromination and Subsequent Suzuki-Miyaura Coupling of 
Pyrazoles. i) To a flask containing pyrazole was added a solution of N-bromosuccinamide (1 
eq.) in acetonitrile (0.2 M). The resulting mixture was stirred for one hour at ambient 
temperature, before being poured into water. The mixture was extracted with ethyl acetate 
and the combined organic layers washed with aqueous sodium hydroxide (1 M). The organic 
layer was dried over MgSO4, filtered and volatiles removed in vacuo. The crude material was 
concentrated into a flask. The flask was then charged with aryl boronate (1.5 eq.), 
XPhosPdG2 (10 mol %), sodium carbonate (2-3.5 eq.) and thoroughly degassed 1,2-
dimethoxyethane:water (1:1, 0.1 M). The mixture was heated at 80 RC for 14 hours, cooled to 
ambient temperature, poured into water and extracted with ethyl acetate. The combined 
organic layers were dried over MgSO4, filtered and volatiles removed in vacuo. Flash silica 
chromatography (gradient starting with 100% 40-60 petroleum ether and ending with 100% 
ethyl acetate in 40-60 petroleum ether) afforded the target pyrazoles. ii) In cases where the 
products obtained were the TBS-protected phenols, the crude Suzuki product was subjected 
to potassium carbonate (3 eq.) in refluxing methanol for 3 hours, before the mixture was 
poured into water and extracted with ethyl acetate. The organic layers were dried over 
MgSO4, filtered and volatiles removed in vacuo, followed by purification. 
General Procedure G: Benzyl Deprotection. A flask was charged with pyrazole and Pd/C 
(10% wt./wt., 100 mg/mmol) and methanol (0.1 M). The flask was flushed with H2 (balloon) 
and stirred for 24-72 hours. The mixture was filtered through celiteTM and concentrated in 
vacuo. Flash silica chromatography (gradient starting with 100% 40-60 petroleum ether and 
ending with 100% ethyl acetate in 40-60 petroleum ether) afforded the target debenzylated 
pyrazoles. 
4-(3-Phenylmethoxy-4-methoxyphenyl)-N-(3,4,5-trimethoxyphenyl)sydnone (2). N-3,4,5-
Trimethoxyphenylsydnone (500 mg, 1.98 mmol) and 1-bromo-3-phenylmethoxy-4-
methoxybenzene (872 mg, 2.97 mmol) were subjected general procedure A, affording 2 as a 
colourless solid (542 mg, 59%). M.p.: 144-146 qC; 1H NMR (400 MHz, CDCl3į+
s), 3.87 (3H, s), 3.92 (3H, s), 4.97 (2H, s), 6.64 (2H, s), 6.81 (1H, d, J = 8.5 Hz), 6.92 (1H, 
dd, J = 8.5, 2.0 Hz), 6.98 (1H, d, J = 2.0 Hz), 7.27-7.35 (5H, m); 13C NMR (101 MHz, 
CDCl3į
130.0, 136.6, 140.7, 148.2, 150.2, 154.2, 167.1; )7,5Ȟmax  2939 (w), 1738 (m), 1602 (m), 
1260 (s), 1234 (s), 1132 (s), 1016 (m), 993 (m); HRMS (ESI-TOF) m/z [M+H]+ calculated for 
C25H25N2O7: 465.1656. Found: 465.1654. 
1-(3,4,5-Trimethoxyphenyl)-3-(trimethylsilyl)-5-(3-phenylmethoxy-4-methoxyphenyl)-
pyrazole (3a, major) and 1-(3,4,5-trimethoxyphenyl)-4-(trimethylsilyl)-5-(3-
phenylmethoxy-4-methoxyphenyl)-pyrazole (3b, minor). Sydnone 2 (136 mg, 0.293 
mmol) and trimethylsilylacetylene (115 mg, 1.17 mmol) were subjected to general procedure 
B, affording an inseparable mixture of pyrazoles 3a and 3b as an orange oil (113 mg, 75%, 
95:5). 1H NMR (400 MHz, CDCl3į+V), 3.69 (6H, s), 3.82 (3H, s),  3.87 (3H, s), 
4.95 (2H, s), 6.51 (1H, s),  6.52 (2H, s), 6.76 (1H, d, J = 1.5 Hz), 6.81-6.88 (2H, m), 7.24-
7.35 (5H, m); 13C NMR (101 MHz, CDCl3į-0.9, 56.0, 56.1, 61.0, 71.1, 103.3, 111.5, 113.4, 
114.6, 122.0, 123.3, 127.0, 127.9, 128.6, 136.1, 136.8, 137.3, 142.9, 147.8, 149.5, 153.2, 
153.7; )7,5Ȟmax  2954 (w), 2836 (w), 1597 (m), 1505 (s), 1229 (s), 1125 (s), 1023 (m), 1005 
(m), 979 (m); HRMS (ESI-TOF) m/z [M+H]+ calculated for C29H35N2O5Si: 519.2310. Found: 
519.2291. 
1-(3,4,5-Trimethoxyphenyl)-5-(3-phenylmethoxy-4-methoxyphenyl)-pyrazole (4). 
Pyrazoles 3a and 3b (86 mg, 0.166 mmol, 95:5) and TBAF in THF (1.7 mL, 1.7 mmol) were 
subjected to general procedure E, affording pyrazole 4 as a yellow oil (50 mg, 67%). 1H 
NMR (400 MHz, CDCl3į (6H, s), 3.84 (3H, s), 3.88 (3H, s),  4.97 (2H, s), 6.39 (1H, d, 
J = 2.0 Hz), 6.49 (2H, s), 6.77 (1H, s), 6.83-6.85 (2H, m), 7.26-7.34 (5H, m), 7.66 (1H, d, J = 
2.0 Hz); 13C NMR (101 MHz, CDCl3į
122.2, 123.1, 127.1, 128.1, 128.7, 135.9, 136.8, 137.3, 140.1, 142.9, 148.0, 149.9, 153.2; 
)7,5Ȟmax  2936 (w), 2836 (w), 1598 (m), 1508 (s), 1454 (m), 1415 (m), 1230 (s), 1118 (s), 
1019 (m), 1002 (m); HRMS (ESI-TOF) m/z [M+H]+ calculated for C26H27BN2O5: 447.1914. 
Found: 447.1925.  
1-(3,4,5-Trimethoxyphenyl)-5-(3-hydroxy-4-methoxyphenyl)-pyrazole (5). Pyrazole 4 
(139 mg, 0.311 mmol) and Pd/C (31 mg) were subjected to general procedure G, affording 
pyrazole 5 as a colourless solid (75 mg, 68%). M.p.: 102-103 qC; 1H NMR (400 MHz, 
CDCl3į (6H, s), 3.83 (3H, s), 3.86 (3H, s),  5.99 (1H, br), 6.42 (1H, d, J = 2.0 Hz), 6.53 
(2H, s), 6.69 (1H, dd, J = 8.5, 2.0 Hz), 6.76 (1H, d, J = 8.5, Hz), 6.87 (1H, d, J = 2.0, Hz), 
7.65 (1H, d, J = 2.0 Hz); 13C NMR (101 MHz, CDCl3į
115.2, 121.0, 123.8, 135.9, 137.2, 140.1, 142.9, 145.6, 146.8, 153.1; )7,5Ȟmax  3133 (br), 
2933 (w), 2840 (w), 1601 (m), 1499 (s), 1458 (m), 1420 (m), 1272 (m), 1232 (s), 1118 (s), 
1010 (m), 1002 (m), 933 (m); HRMS (ESI-TOF) m/z [M+H]+ calculated for C19H21N2O5: 
357.1445. Found: 357.1446; HPLC: Ret. Time: 13.65 min, Purity 96.3%. 
N-(3-Hydroxy-4-methoxyphenyl)sydnone (6). 2-((3-Hydroxy-4-methoxyphenyl)amino) 
acetic acid (0.97 g, 4.9 mmol) was dissolved in 1,2-dimethoxethane (20 mL) and 
isoamylnitrite (0.58 g, 4.9 mmol)  was added and the reaction stirred for 3 hours at room 
temperature. Volatiles were removed in vacuo at <30 RC and the crude material triturated 
with petroleum ether:diethyl ether (20:1). Caution nitrosamines are highly toxic and 
carcinogenic. The crude material was suspended in dichloromethane (20 mL) and cooled at 0 
RC. Trifluoracetic anhydride (1.56 g, 7.41 mmol) was added and the reaction stirred for 1.5 
hours at r.t. A small amount of water was added and the mixture basified with sodium 
bicarbonate and extracted with dichloromethane. The combined organic layers were dried 
over MgSO4 and volatiles removed in vacuo. 6 was isolated as a brown solid (0.29 g, 28%). 
The product could be further purified by recrystallization from ethanol. M.p.: 205-209 qC 
(dec.); 1H NMR (400 MHz, DMSO-d6į+V+GJ = 9.0 Hz), 7.30 (1H, d, 
J = 2.5 Hz), 7.36 (1H, dd, J = 2.5, 9.0 Hz), 7.66 (1H, s), 9.99 (1H, s). 13C NMR (101 MHz, 
DMSO-d6 į          )7,5 Ȟmax 3248 
(br), 2924 (w), 1755 (s), 1720 (s), 1517 (s), 1285 (s), 1031 (m); HRMS calculated for 
C9H9N2O4 (ES+)(+H+): 209.0562. Found: 209.0553. 
4-(3,4,5-Trimethoxyphenyl)-N-(3-hydroxy-4-methoxyphenyl)sydnone. N-(3-Hydroxy-4-
methoxyphenyl)sydnone (473 mg, 2.27 mmol) and 5-bromo-1,2,3-trimethoxybenzene (842 
mg, 3.41 mmol) were subjected to general procedure A affording, 4-(3,4,5-
trimethoxyphenyl)-N-(3-hydroxy-4-methoxyphenyl)sydnone as a colourless solid (402 mg, 
47%). M.p.: 196-197 °C; 1H NMR (400 MHz, CDCl3į+V+V+
s), 5.94 (1H, s), 6.59 (2H, s), 6.92-7.05 (2H, m), 7.09 (1H, s); 13C NMR (101 MHz, CDCl3į
56.1, 56.5, 61.0, 104.7, 108.0, 111.0, 111.7, 117.2, 119.9, 127.8, 138.5, 147.0, 149.5, 153.3, 
)7,5Ȟmax 3295 (br), 3082 (w), 2940 (w), 2836 (w), 1710 (s), 1600 (w), 1581 (m), 
1509 (s), 1229 (s), 1125 (s) 1014 (m), 998 (m); HRMS calculated for C18H19N2O7 
(ES+)(+H+): 375.1192. Found: 375.1181. 
4-(3,4,5-Trimethoxyphenyl)-N-(3-phenylmethoxy-4-methoxyphenyl)sydnone (7). A 
mixture of 4-(3,4,5-trimethoxyphenyl)-N-(3-hydroxy-4-methoxyphenyl)sydnone (402 mg, 
1.07 mmol),benzyl bromide (368 mg, 2.15 mmol) and Hünigs base (278 mg, 2.15 mmol) 
were heated at 130 RC for 2 hours. The reaction was allowed to cool to ambient temperature 
and water was added. The mixture was extracted with dichloromethane and the combined 
organic layers washed with saturated ammonium chloride and brine, before drying over 
MgSO4 and concentrating in vacuo. Flash silica chromatography (gradient starting with 100% 
40-60 petroleum ether and ending with 40% ethyl acetate in 40-60 petroleum ether) afforded 
sydnone 7 as a yellow solid (296 mg, 60%). M.p.: 58-60 qC; 1H NMR (400 MHz, CDCl3į
3.62 (6H, s), 3.83 (3H, s), 3.96 (3H, s), 5.09 (2H, s), 6.51 (2H, s), 6.98-7.03 (2H, m), 7.09 
(1H, dd, J = 8.5, 2.5 Hz), 7.29-7.36 (5H, m); 13C NMR (101 MHz, CDCl3į
71.6, 104.5, 107.8, 110.6, 111.7, 118.3, 119.9, 127.3 (x2 C),  128.6, 128.9, 135.5, 138.5, 
149.1, 152.5, 153.4, 167.1; )7,5 Ȟmax  2934 (w), 2836 (w), 1728 (s), 1581 (m), 1512 (s), 
1226 (s), 1123 (s), 999 (s); HRMS (ESI-TOF) m/z [M+H]+ calculated for C25H25N2O7: 
465.1656. Found: 465.1668.  
1-(3-Phenylmethoxy-4-methoxyphenyl)-3-(trimethylsilyl)-5-(3,4,5-trimethoxyphenyl)-
pyrazole (8a, major) and 1-(3-phenylmethoxy-4-methoxyphenyl)-4-(trimethylsilyl)-5-
(3,4,5-trimethoxyphenyl)-pyrazole (8b, minor). Sydnone 7 (290 mg, 0.624 mmol) and 
trimethylsilylacetylene (245 mg, 2.50 mmol) were subjected to general procedure B, 
affording an inseparable mixture of pyrazoles 8a and 8b as an orange oil (256 mg, 79%, 
95:5). 1H NMR (400 MHz, CDCl3į+V), 3.65 (6H, s), 3.84 (3H, s),  3.87 (3H, s), 
5.02 (2H, s), 6.38 (2H, s), 6.56 (1H, s), 6.83 (1H, d, J = 8.5 Hz), 6.88 (1H, dd, J = 8.5, 2.5 
Hz), 6.95 (1H, d, J = 2.5 Hz), 7.27-7.34 (5H, m); 13C NMR (101 MHz, CDCl3į-0.9, 56.1, 
56.4, 61.0, 71.3, 106.0, 111.5, 112.0, 113.3, 118.6, 126.3, 127.3, 128.1, 128.6, 133.6, 136.6, 
137.8, 143.0, 148.3, 149.2, 153.1, 153.6; )7,5Ȟmax  2951 (w), 2834 (w), 1584 (m), 1514 (s), 
1236 (s), 1126 (s), 1005 (m), 978 (m); HRMS (ESI-TOF) m/z [M+H]+ calculated for 
C29H35N2O5Si: 519.2310. Found: 519.2314. 
1-(3-Phenylmethoxy-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-pyrazole (9). 
Pyrazoles 8a and 8b (256 mg, 0.494 mmol, 95:5) and TBAF in THF (5 mL, 5 mmol) were 
subjected to general procedure E, affording pyrazole 9 as a yellow oil (137 mg, 62%).  
Product was contaminated with ~10% unknown by-product. 1H NMR (400 MHz, CDCl3į
3.64 (6H, s), 3.83 (3H, s), 3.86 (3H, s),  5.01 (2H, s), 6.38 (2H, s), 6.45 (1H, d, J = 2.0 Hz), 
6.81-6.84 (2H, m), 6.93-6.97 (1H, m), 7.25-7.36 (5H, m), 7.65 (1H, d, J = 2.0 Hz); 13C NMR 
(101 MHz, CDCl3į
127.3, 128.0, 128.6, 133.3, 136.5, 139.9, 142.9, 148.2, 149.1, 153.0; )7,5Ȟmax  2934 (w), 
2836 (w), 1584 (m), 1512 (s), 1414 (m), 1236 (s), 1121 (s), 1002 (m), 910 (m); HRMS (ESI-
TOF) m/z [M+H]+ calculated for C26H27BN2O5: 447.1914. Found: 447.1914. 
1-(3-Hydroxy-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-pyrazole (10). Pyrazole 9 
(137 mg, 0.307 mmol) and Pd/C (31 mg) for 24 hours were subjected to general procedure G, 
affording pyrazole 10 as a colourless solid (76 mg, 69%). M.p.: 55-58 qC; 1H NMR (400 
MHz, CDCl3į+V+V+V+EU), 6.43 (2H, s), 6.46 (1H, 
d, J = 2.0 Hz), 6.75 (1H, dd, J = 8.5, 2.5 Hz), 6.78 (1H, d, J = 8.5, Hz), 6.97 (1H, d, J = 2.5, 
Hz), 7.66 (1H, d, J = 2.0 Hz); 13C NMR (101 MHz, CDCl3į
110.4, 112.7, 117.5, 126.0, 133.9, 138.0, 139.9, 143.1, 145.9, 146.3, 153.1; )7,5Ȟmax  3146 
(br), 2941 (w), 2836 (w), 1585 (m), 1511 (s), 1498 (s), 1416 (m), 1239 (s), 1120 (s), 1000 
(m); HRMS (ESI-TOF) m/z [M+H]+ calculated for C19H21N2O5: 357.1445. Found: 357.1444; 
HPLC: Ret. Time: 13.54 min, Purity 95.2%. 
4-(3,4,5-Trimethoxyphenyl)-N-methylsydnone (11). N-Methylsydnone (250 mg, 2.50 
mmol) and 5-bromo-1,2,3-trimethoxybenzene (926 mg, 3.75 mmol) were subjected to general 
procedure A, affording 11 as a colourless solid (571 mg, 86%). M.p.: 123-124 qC; 1H NMR 
(400 MHz, CDCl3į H, s), 3.87 (6H, s), 4.12 (3H, s), 6.74 (2H, s); 13C NMR (101 
MHz, CDCl3į )7,5Ȟmax  2932 
(w), 2858 (w), 1726 (s), 1585 (m), 1241 (m), 1225 (m), 1124 (s), 998 (m); HRMS (ESI-TOF) 
m/z [M+H]+ calculated for C12H15N2O5: 267.0981. Found: 267.0970. 
4-(3,4,5-Trimethoxyphenyl)-N-benzylsydnone (12). N-Benzylsydnone (500 mg, 2.84 
mmol) and 5-bromo-1,2,3-trimethoxybenzene (1.05 g, 4.26 mmol) were subjected to general 
procedure A, affording 12 as a colourless solid (570 mg, 59%). M.p.: 101 qC; 1H NMR (400 
MHz, CDCl3į+V), 3.84 (3H, s), 5.52 (2H, s), 6.52 (2H, s), 7.18-7.24 (2H, m), 7.37-
7.43 (3H, m); 13C NMR (101 MHz, CDCl3į
129.5, 129.5, 132.0, 139.2, 153.8, 167.6; FTIRȞmax  2829 (w), 1727 (s), 1712 (s), 1578 (m), 
1521 (m), 1223 (s), 1131 (s), 1000 (s); HRMS (ESI-TOF) m/z [M+H]+ calculated for 
C18H19N2O5: 343.1294. Found: 343.1278. 
4-(3-Phenylmethoxy-4-methoxyphenyl)-N-methylsydnone (13). N-Methylsydnone (500 
mg, 5.00 mmol) and 1-bromo-3-phenylmethoxy-4-methoxybenzene (2.2 g, 7.5 mmol) were 
subjected to general procedure A affording 13 as a tan solid (1.105 g, 71%). M.p.: 99 qC; 1H 
NMR (400 MHz, CDCl3į (3H, s), 3.92 (3H, s), 5.19 (2H, s), 6.96 (1H, d, J = 8.5 Hz), 
7.04 (1H, d, J = 2.0 Hz), 7.10 (1H, dd, J = 8.5, 2.0 Hz), 7.27-7.33 (1H, m), 7.34-7.40 (2H, 
m), 7.41-7.47 (2H, m); 13C NMR (101 MHz, CDCl3į
116.7, 121.4, 127.4, 128.1, 128.8, 136.8, 148.3, 150.6, 167.4; )7,5Ȟmax  2970 (w), 1723 (s), 
1532 (m), 1450 (m), 1380 (m), 1305 (m), 1230 (m), 1225 (m), 1150 (s), 990 (s); HRMS (ESI-
TOF) m/z [M+H]+ calculated for C17H17N2O4: 313.1188. Found: 313.1185. 
4-(3-Phenylmethoxy-4-methoxyphenyl)-N-benzylsydnone (14). N-Benzylsydnone (1.00 g, 
5.68 mmol) and 1-bromo-3-phenylmethoxy-4-methoxybenzene (2.50 g, 8.51 mmol) were 
subjected to general procedure A, affording 14 as a tan solid (1.21 g, 55%). M.p.: 144-145 
qC; 1H NMR (400 MHz, CDCl3į (3H, s), 5.01 (2H, s), 5.34 (2H, s), 6.87 (1H, d, J = 
2.0 Hz), 6.91 (1H, d, J = 8.5 Hz), 6.96 (1H, dd, J = 8.5, 2.0 Hz), 7.06-7.11 (2H, m), 7.27-7.40 
(8H, m); 13C NMR (101 MHz, CDCl3į
127.5, 127.6, 128.2, 128.8, 129.4, 129.5, 131.7, 136.6, 148.4, 150.8, 167.7; FTIRȞmax  3008 
(w), 2836 (w), 1720 (s), 1703 (m), 1260 (m), 1226 (m), 1176 (m), 1023 (s); HRMS (ESI-
TOF) m/z [M+H]+ calculated for C23H21N2O4: 389.1501. Found: 389.1519. 
1-(Methyl)-3-(trimethylsilyl)-4-(pinacolatoborolane)-5-(3,4,5-trimethoxyphenyl)-
pyrazole (15a, major) and 1-(4-methyl)-3-(trimethylsilyl)-5-(3,4,5-trimethoxyphenyl)-
pyrazole (15b, minor). Sydnone 11 (200 mg, 0.751 mmol) and 4,4,5,5-tetramethyl-2-[2-
(trimethylsilyl)ethynyl]-1,3,2-dioxaborolane (337 mg, 1.50 mmol) were subjected to general 
procedure C,  affording an inseparable mixture of pyrazoles 15a and 15b as a yellow oil (309 
mg, 92% 5:1). 1H NMR (400 MHz, CDCl3į+V), 1.18 (12H, s), 3.80 (3H, s), 3.85 
(6H, s),  3.90 (3H, s), 6.59 (2H, s); 13C NMR (101 MHz, CDCl3 į -0.4, 25.0, 37.2, 56.2, 
61.1, 83.0, 107.8, 126.9, 138.1, 150.8, 152.6, 158.8; )7,5Ȟmax  2976 (m), 1585 (m), 1497 
(s), 1411 (s), 1240 (s), 1128 (s), 1048 (m); HRMS (ESI-TOF) m/z [M+H]+ calculated for 
C22H36N2O5Si: 447.2481. Found: 447.2488. 
1-(Benzyl)-3-(trimethylsilyl)-4-(pinacolatoborolane)-5-(3,4,5-trimethoxyphenyl)-
pyrazole (16a, major) and 1-(benzyl)-3-(trimethylsilyl)-5-(3,4,5-trimethoxyphenyl)-
pyrazole (16b, minor). Sydnone 12 (200 mg, 0.584 mmol) and 4,4,5,5-tetramethyl-2-[2-
(trimethylsilyl)ethynyl]-1,3,2-dioxaborolane (262 mg, 1.17 mmol) were subjected to general 
procedure C,  affording an inseparable mixture of pyrazoles 16a and 16b was isolated as a 
yellow oil (202 mg, 66%, 9:1). 1H NMR (400 MHz, CDCl3) į (9H, s), 1.19 (12H, s), 
3.63 (6H, s), 3.87 (3H, s),  5.28 (2H, s), 6.40 (2H, s) 7.05 (2H, d, J = 7.0 Hz), 7.17-7.29 (3H, 
m); 13C NMR (101 MHz, CDCl3 į -0.3, 25.0, 53.1, 55.9, 61.0, 83.0, 107.7, 112.8, 127.0, 
127.3, 128.5, 138.0, 138.5, 150.9, 152.4, 158.8; )7,5Ȟmax  2976 (w), 1585 (m), 1496 (m), 
1236 (s), 1124 (s), 1038 (s); HRMS (ESI-TOF) m/z [M+H]+ calculated for C28H4011BN2O5Si: 
523.2794. Found: 523.2801. 
1-(Methyl)-3-(trimethylsilyl)-4-(pinacolatoborolane)-5-(3-phenylmethoxy-4-
methoxyphenyl)-pyrazole (17a, major) and 1-(methyl)-3-(trimethylsilyl)-5-(3-
phenylmethoxy-4-methoxyphenyl)-pyrazole (17b, minor). Sydnone 13 (200 mg, 0.640 
mmol) and 4,4,5,5-tetramethyl-2-[2-(trimethylsilyl)ethynyl]-1,3,2-dioxaborolane (287 mg, 
1.28 mmol) were subjected to general procedure C, affording an inseparable mixture of 
pyrazoles 17a and 17b as a yellow oil (230 mg, 73%, 4:1). 1H NMR (400 MHz, CDCl3į
0.37 (9H, s), 1.20 (12H, s), 3.57 (3H, s), 3.94 (3H, s),  5.18 (2H, s), 6.91-6.94 (3H, m) 7.28-
7.32 (1H, m), 7.33-7.39 (2H, m), 7.41-7.46 (2H, m); 13C NMR (101 MHz, CDCl3 į -0.4, 
25.0, 36.9, 56.1, 71.0, 82.9, 110.9, 116.5, 122.0, 123.6, 127.3, 128.0, 128.7, 137.1, 147.1, 
149.7, 150.7, 158.7; )7,5Ȟmax  2977 (w), 1498 (m), 1311 (s), 1250 (s), 1139 (s), 1046 (m), 
1026 (m); HRMS (ESI-TOF) m/z [M+H]+ calculated for C27H3811BN2O4Si: 493.2694. Found: 
493.2718. 
1-(Benzyl)-3-(trimethylsilyl)-4-(pinacolatoborolane)-5-(3-phenylmethoxy-4-
methoxyphenyl)-pyrazole (18a, major) and 1-(benzyl)-3-(trimethylsilyl)-5-(3-
phenylmethoxy-4-methoxyphenyl)-pyrazole (18b, minor). Sydnone 14 (200 mg, 0.515 
mmol) and 4,4,5,5-tetramethyl-2-[2-(trimethylsilyl)ethynyl]-1,3,2-dioxaborolane (231 mg, 
1.03 mmol) were subjected to general procedure C, affording an inseparable mixture of 
pyrazoles 18a and 18b as a yellow oil (187 mg, 64%, 9:1). 1H NMR (400 MHz, CDCl3į
0.39 (9H, s), 1.19 (12H, s), 3.91 (3H, s),  4.90 (2H, s), 5.16 (2H, s), 6.78-6.82 (2H, m), 6.84 
(1H, d, J = 8.0 Hz), 6.92-6.98 (2H, m), 7.18-7.24 (2H, m), 7.27-7.41 (6H, m); 13C NMR (101 
MHz, CDCl3į -0.3, 25.0, 52.9, 56.1, 70.7, 83.0, 110.9, 115.9, 123.6, 123.9, 127.1, 127.2, 
127.4, 128.0, 128.4, 128.7, 137.1, 138.3, 147.2, 149.7, 150.8, 158.7; )7,5Ȟmax  2977 (w), 
1497 (m), 1452 (m), 1250 (s), 1141 (s), 1029 (m) 908 (s); HRMS (ESI-TOF) m/z [M+H]+ 
calculated for C33H4211BN2O4Si: 569.3007. Found: 569.3010. 
1-(Methyl)-3-(trimethylsilyl)-4-(3-phenylmethoxy-4-methoxyphenyl)-5-(3,4,5-
trimethoxyphenyl)-pyrazole (19, major) and 1-(methyl)-3-(trimethylsilyl)-5-(3,4,5-
trimethoxyphenyl)-pyrazole (15b, minor). Pyrazoles 15a and 15b (498 mg, 1.12 mmol) 
and 1-bromo-3-phenylmethoxy-4-methoxybenzene (491 mg, 1.67 mmol) were subjected to 
general procedure D,  affording an inseparable mixture of pyrazoles 19 and 15b as a yellow 
oil (409 mg, 69%, 3:1). 1H NMR (400 MHz, CDCl3į+V+V+V
3.87 (3H, s), 3.88 (3H, s), 5.00 (2H, s), 6.34 (2H, s) 6.68 (1H, d, J = 2.0 Hz), 6.71 (1H, d, J = 
8.0, 2.0 Hz), 6.79 (1H, d, J = 8.0 Hz), 7.25-7.35 (5H, m); 13C NMR (101 MHz, CDCl3į-
0.2, 37.7, 56.1, 56.2, 61.0, 71.1, 106.3, 107.3, 111.3, 112.6, 116.8, 123.8, 125.7, 127.1, 127.7, 
127.9, 128.6, 137.2, 141.3, 147.5, 148.6, 150.5, 153.1; )7,5Ȟmax  2957 (w), 2934 (w), 1580 
(m), 1237 (s), 1127 (s), 1008 (m); HRMS (ESI-TOF) m/z [M+H]+ calculated for 
C30H37N2O5Si: 533.2472. Found: 533.2469.  
1-(Benzyl)-3-(trimethylsilyl)-4-(3-phenylmethoxy-4-methoxyphenyl)-5-(3,4,5-
trimethoxyphenyl)-pyrazole (20, major) and 1-(benzyl)-3-(trimethylsilyl)-5-(3,4,5-
trimethoxyphenyl)-pyrazole (16b, minor). Pyrazoles 16a and 16b (307 mg, 0.587 mmol) 
and 1-bromo-3-phenylmethoxy-4-methoxybenzene (258 mg, 0.881 mmol) were subjected to 
general procedure D,  affording an inseparable mixture of pyrazoles 20 and 16b as a yellow 
oil (257 mg, 72%, 9:1). 1H NMR (400 MHz, CDCl3į+V+V+V
3.86(3H, s), 4.99 (2H, s), 5.33 (2H, s), 6.18 (2H, s) 6.72-6.77 (2H, m), 6.80 (1H, d, J = 8.0 
Hz), 7.12-7.17 (2H, m), 7.22-7.38 (8H, m); 13C NMR (101 MHz, CDCl3į-0.2, 53.6, 55.8, 
56.0, 60.9, 71.1, 106.1, 107.3, 111.2, 116.6, 123.6, 125.7, 126.4, 127.0, 127.1, 127.4, 127.8, 
128.5, 128.6, 137.1, 137.7, 138.5, 141.0, 147.4, 148.5, 150.7, 152.8; )7,5Ȟmax  2956 (w), 
2835 (w), 1583 (m), 1495 (m), 1244 (s), 1125 (s), 1026 (m), 1004 (m), 907 (m); HRMS (ESI-
TOF) m/z [M+H]+ calculated for C36H41N2O5Si: 609.2779. Found: 609.2772.  
1-(Methyl)-3-(trimethylsilyl)-4-(3,4,5-trimethoxyphenyl)-5-(3-phenylmethoxy-4-
methoxyphenyl)-pyrazole (21, major) and 1-(methyl)-3-(trimethylsilyl)-5-(3-
phenylmethoxy-4-methoxyphenyl)-pyrazole (17b, minor). Pyrazoles 17a and 17b (215 
mg, 0.437 mmol) and 5-bromo-1,2,3-trimethoxybenzene (218 mg, 0.883 mmol) were 
subjected to general procedure D,  affording an inseparable mixture of pyrazoles 21 and 17b 
was isolated as a yellow oil (137 mg, 60%, 4:1). 1H NMR (400 MHz, CDCl3į (9H, s), 
3.68 (9H, s), 3.83 (3H, s), 3.87 (3H, s), 5.01 (2H, s), 6.32 (2H, s) 6.68 (1H, d, J = 2.0 Hz), 
6.77 (1H, d, J = 8.5, 2.0 Hz), 6.85 (1H, d, J = 8.5 Hz), 7.25-7.38 (5H, m); 13C NMR (101 
MHz, CDCl3į -0.2, 37.3, 56.0, 56.3, 61.0, 71.0, 104.7, 107.7, 111.5, 116.0, 122.6, 123.2, 
127.0, 127.9, 128.6, 130.7, 136.8, 140.8, 147.6, 149.6, 149.8, 152.5, 153.4; FTIRȞmax  2934 
(w), 1580 (m), 1493 (m), 1233 (s), 1125 (s), 1006 (m); HRMS (ESI-TOF) m/z [M+H]+ 
calculated for C30H37N2O5Si: 533.2472. Found: 533.2497.  
1-(Benzyl)-3-(trimethylsilyl)-4-(3,4,5-trimethoxyphenyl)-5-(3-phenylmethoxy-4-
methoxyphenyl)-pyrazole (22) and  1-(benzyl)-3-(trimethylsilyl)-5-(3-phenylmethoxy-4-
methoxyphenyl)-pyrazole (18b). Pyrazoles 18a and 18b (162 mg, 0.285 mmol) and 5-
bromo-1,2,3-trimethoxybenzene (136 mg, 0.550 mmol) were subjected to general procedure 
D,  affording an inseparable mixture of pyrazoles 22 and 18b as a yellow oil (85 mg, 49%, 
3:1). 1H NMR (400 MHz, CDCl3į (9H, s), 3.66 (6H, s), 3.82 (3H, s), 3.86 (3H, s), 4.78 
(2H, s), 5.22 (2H, s), 6.31 (2H, s) 6.56 (1H, d, J = 2.0 Hz), 6.62 (1H, d, J = 8.5, 2.0 Hz), 6.77 
(1H, d, J = 8.5 Hz), 7.08 (2H, dd, J = 9.0, 7.0 Hz), 7.22-7.35 (8H, m); 13C NMR (101 MHz, 
CDCl3į -0.1, 53.5, 56.1, 56.4, 61.1, 70.7, 107.7, 109.1, 111.5, 115.8, 122.1, 126.7, 127.2 
(x2 C), 127.5, 128.0, 128.6 (x2 C), 130.6, 136.8, 138.2, 140.9, 147.7, 149.7, 150.3, 152.5, 
154.0; )7,5 Ȟmax  2955 (w), 2934 (w), 2834 (w), 1581 (m), 1494 (m), 1232 (s), 1124 (s), 
1006 (m); HRMS (ESI-TOF) m/z [M+H]+ calculated for C36H41N2O5Si: 609.2784. Found: 
609.2785. 
1-(Methyl)-4-(3-phenylmethoxy-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-pyrazole 
(23a) and 1-(methyl)-5-(3,4,5-trimethoxyphenyl)-pyrazole (23b). Pyrazoles 19 and 15b 
(211 mg, 0.396 mmol, 3:1) and TBAF in THF (4 mL, 4 mmol) were subjected to general 
procedure E,  affording a mixture of pyrazole 23a and 23b as a yellow oil (101 mg, 55%, 
95:5). 1H NMR (400 MHz, CDCl3į (6H, s), 3.83 (3H, s), 3.87 (3H, s), 3.89 (3H, s),  
4.89 (2H, s), 6.48 (2H, s), 6.71 (1H, d, J = 2.0 Hz), 6.75-6.85 (2H, m), 7.20-7.32 (5H, m), 
7.63 (1H, s); 13C NMR (101 MHz, CDCl3į
113.3, 120.0, 120.6, 125.8, 126.1, 127.1, 127.9, 128.6, 137.1, 137.2, 138.5, 139.4, 148.0, 
148.2; )7,5Ȟmax  2935 (w), 2835 (w), 1583 (m), 1409 (m), 1236 (s), 1123 (s), 1002 (m); 
HRMS (ESI-TOF) m/z [M+H]+ calculated for C27H29N2O5: 461.2076. Found: 461.2090.  
1-(Benzyl)-4-(3-phenylmethoxy-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-pyrazole 
(24). Pyrazoles 20 and 16b (244 mg, 0.401 mmol, 9:1) and TBAF in THF (4 mL, 4 mmol) 
were subjected to general procedure E, affording pyrazole 24 as a yellow oil (137 mg, 64%). 
1H NMR (400 MHz, CDCl3į+V+V+V+s), 5.22 (2H, 
s), 6.33 (2H, s), 6.76 (1H, d, J = 2.0 Hz), 6.79 (1H, d, J = 8.5 Hz), 6.85 (1H, dd, J = 8.5, 2.0 
Hz), 7.04-7.08 (2H, m), 7.23-7.32 (8H, m), 7.74 (1H, s); 13C NMR (101 MHz, CDCl3į
56.1 (x2 C), 61.1, 70.8, 107.5, 112.0, 113.1, 119.8, 120.8, 125.6, 125.8, 127.0, 127.1, 127.6, 
127.8, 128.5, 128.6, 137.1, 137.6, 138.0, 138.4, 139.4, 148.0, 148.2, 153.5; )7,5Ȟmax  2999 
(w), 2934 (w), 2836 (w), 1580 (m), 1517 (m), 1451 (m), 1220 (s), 1136 (s), 1106 (m), 1024 
(m), 1001 (m); HRMS (ESI-TOF) m/z [M+H]+ calculated for C33H33N2O5: 537.2384. Found: 
537.2386. 
1-(Methyl)-4-(3,4,5-trimethoxyphenyl)-5-(3-phenylmethoxy-4-methoxyphenyl)-pyrazole 
(25). Pyrazoles 21 and 17b (137 mg, 0.257 mmol, 4:1) and TBAF in THF (2.6 mL, 2.6 
mmol) were subjected to general procedure E,  affording pyrazole 25 as an orange oil (66 mg, 
56%). 1H NMR (400 MHz, CDCl3į+V+V+V+V
5.11 (2H, s), 6.36 (2H, s), 6.80 (1H, d, J = 2.0 Hz), 6.87 (1H, dd, J = 8.0, 2.0 Hz), 6.96 (1H, 
d, J = 8.0 Hz), 7.24-7.38 (5H, m), 7.62 (1H, s); 13C NMR (101 MHz, CDCl3į
56.2, 61.0, 71.2, 104.3, 112.0, 116.2, 120.8, 122.7, 123.6, 127.2, 128.1, 128.7 (x2 C), 136.4, 
136.6, 137.0, 139.7, 148.1, 150.3, 153.1; )7,5 Ȟmax  3002 (w), 2934 (w), 1584 (m), 1521 
(m), 1418 (m), 1373 (m), 1253 (s), 1124 (s), 1021 (m), 1007 (m); HRMS (ESI-TOF) m/z 
[M+H]+ calculated for C27H29N2O5: 461.2071. Found: 461.2070. 
1-(Benzyl)-4-(3,4,5-trimethoxyphenyl)-5-(3-phenylmethoxy-4-methoxyphenyl)-pyrazole 
(26). Pyrazoles 22 and 18b (158 mg, 0.260 mmol, 4:1) and TBAF in THF (2.6 mL, 2.6 
mmol) were subjected to general procedure E,  affording pyrazole 26 as an orange oil (103 
mg, 74%). 1H NMR (400 MHz, CDCl3įH, s), 3.80 (3H, s), 3.91 (3H, s), 4.88 (2H, 
s), 5.13 (2H, s), 6.37 (2H, s), 6.67 (1H, d, J = 2.0 Hz), 6.79 (1H, dd, J = 8.0, 2.0 Hz), 6.90 
(1H, d, J = 8.0 Hz), 6.98-7.03 (2H, m), 6.24-7.33 (8H, m), 7.79 (1H, s); 13C NMR (101 MHz, 
CDCl3į
127.7, 128.1, 128.6, 128.7 (x2 C), 136.5, 136.6, 137.6, 137.7, 140.0, 148.1, 150.3, 153.2; 
)7,5Ȟmax  2935 (w), 2835 (w), 1583 (m), 1520 (m), 1454 (m), 1373 (m), 1245 (s), 1123 (s), 
1002 (s); HRMS (ESI-TOF) m/z [M+H]+ calculated for C33H33N2O5: 537.2384. Found: 
537.2383.  
1-(Methyl)-4-(3-hydroxy-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-pyrazole (27). 
Pyrazoles 23a and 23b (100 mg, 0.217 mmol) and Pd/C (22 mg) were subjected to general 
procedure G,  affording pyrazole 27 was isolated as a colourless solid (47 mg, 58%). M.p.: 
210 qC; 1H NMR (400 MHz, CDCl3įH, s), 3.79 (6H, s), 3.85 (3H, s), 3.92 (3H, s), 
5.57 (1H, s), 6.50 (2H, s), 6.66 (1H, dd, J = 8.5, 2.0 Hz), 6.72 (1H, d, J = 8.5 Hz), 6.85 (1H, 
d, J = 2.0 Hz), 7.67 (1H, s); 13C NMR (101 MHz, CDCl3 į
110.8, 113.8, 119.1, 120.6, 125.9, 126.5, 137.4, 138.4, 139.5, 145.3, 145.6, 153.6; )7,5Ȟmax  
3347 (br), 1582 (m), 1458 (m), 1406 (m), 1270 (m), 1232 (s), 1129 (s), 1028 (m), 997 (m); 
HRMS (ESI-TOF) m/z [M+H]+ calculated for C20H23N2O5: 371.1607. Found: 371.1611; 
HPLC: Ret. Time: 11.31 min, Purity 98.5%. 
4-(3-Hydroxy-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-pyrazole (28) and 1-
(benzyl)-4-(3-hydroxy-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-pyrazole (29). 
Pyrazole 24 (126 mg, 0.235 mmol) and Pd/C (24 mg) were subjected to general procedure G,  
affording pyrazole 28 as a colourless solid (25 mg, 30%) and pyrazole 29 as a colourless 
solid (23 mg, 22%). 28: M.p.: 198-200 qC; 1H NMR (400 MHz, CDCl3į+V
(3H, s), 3.90 (3H, s), 6.71 (2H, s), 6.81 (2H, app. d, J = 1.0 Hz), 6.96 (1H, app. t, J = 1.0 Hz), 
7.65 (1H, s); 13C NMR (101 MHz, CDCl3į (x2 C), 61.1, 105.4, 105.6, 110.8, 115.2, 
119.8, 120.7, 126.5, 127.1, 129.9, 138.1, 145.7, 145.8, 153.4; )7,5Ȟmax  3251 (m), 2966 (w), 
2937 (w), 1587 (m), 1412 (m), 1274 (m), 1234 (s), 1121 (s), 1028 (m), 994 (m); HRMS (ESI-
TOF) m/z [M+H]+ calculated for C19H20N2O5: 357.1445. Found: 357.1443; HPLC: Ret. Time: 
11.76 min, Purity 98.2%. 29: M.p.: 126 qC; 1H NMR (400 MHz, CDCl3į+V
(3H, s), 3.89 (3H, s), 5.22 (2H, s), 5.56 (1H, s), 6.33 (2H, s), 6.65-6.74 (2H, m), 6.87 (1H, d, 
J = 1.5 Hz), 7.06 (1H, d, J = 7.0 Hz), 7.19-7.33 (4H, m), 7.77 (1H, s); 13C NMR (101 MHz, 
CDCl3 į   (x2 C), 61.1, 107.6, 110.8, 113.6, 119.0, 120.8, 125.7, 126.5, 127.0, 
127.6, 128.7, 138.0, 138.1, 138.5, 139.7, 145.3, 145.6, 153.4; FTIRȞmax  3423 (m), 2926 (m), 
2835 (w), 1579 (m), 1500 (m), 1231 (m), 1216 (m), 1124 (s), 1028 (m), 1000 (m); HRMS 
(ESI-TOF) m/z [M+H]+ calculated for C26H26N2O5: 447.1914. Found: 447.1922; HPLC: Ret. 
Time: 16.32 min, Purity 95.7%. 
4-(3-Hydroxy-4-methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-pyrazole (28). Pyrazole 38 
(79 mg, 0.18 mmol) and Pd/C (18 mg) were subjected to general procedure G, affording 
pyrazole 28 as a colourless solid (18 mg, 29%). See above for characterization. 
1-(Methyl)-4-(3,4,5-trimethoxyphenyl)-5-(3-hydroxy-4-methoxyphenyl)-pyrazole (30). 
Pyrazole 25 (177 mg, 0.384 mmol) and Pd/C (38 mg) were subjected to general procedure G,  
affording pyrazole 30 as a colourless solid (96 mg, 67%). M.p.: 149-150 qC; 1H NMR (400 
MHz, CDCl3į3.64 (6H, s), 3.74 (3H, s), 3.79 (3H, s),  3.92 (3H, s), 6.38 (1H, br), 6.41 (2H, 
s), 6.79 (1H, dd, J = 8.0, 2.0 Hz), 6.89-6.95 (2H, m), 7.68 (1H, s); 13C NMR (101 MHz, 
CDCl3į, 137.0, 
139.8, 146.1, 147.3, 153.1; )7,5Ȟmax  3269 (br), 2940 (w), 1583 (m), 1373 (m), 1272 (m), 
1227 (m), 1173 (m), 1123 (s), 1007 (m); HRMS (ESI-TOF) m/z [M+H]+ calculated for 
C20H23N2O5: 371.1607. Found: 371.1605; HPLC: Ret. Time: 13.06 min, Purity 94.4%. 
4-(3,4,5-Trimethoxyphenyl)-5-(3-hydroxy-4-methoxyphenyl)-pyrazole (31) and 1-
(benzyl)-4-(3,4,5-trimethoxyphenyl)-5-(3-hydroxy-4-methoxyphenyl)-pyrazole (32). 
Pyrazole 26 (66 mg, 0.123 mmol) and Pd/C (15 mg) were subjected to general procedure G, 
affording pyrazole 31 as a colourless solid (12 mg, 27%) and pyrazole 32 as a tan solid (15 
mg, 27%). 31: M.p.: 90-93 qC; 1H NMR (400 MHz, CDCl3į+V+V
(3H, s), 6.51 (2H, s), 6.80 (1H, d, J = 8.5 Hz), 6.94 (1H, dd, J = 8.5, 2.0 Hz), 7.13 (1H, d, J = 
2.0 Hz), 7.67 (1H, s); 13C NMR (101 MHz, CDCl3į
119.6, 120.6, 124.2, 128.8, 135.9, 136.9, 142.6, 145.8, 147.1, 153.3; )7,5Ȟmax  3282 (br), 
2934 (w), 2838 (w), 1584 (m), 1449 (m), 1411 (m), 1251 (m), 1231 (m), 1122 (s), 1019 (m); 
HRMS (ESI-TOF) m/z [M+H]+ calculated for C19H20N2O5: 357.1445. Found: 357.1440; 
HPLC: Ret. Time: 12.08 min, Purity 95.1%. 32: M.p.: 167-168 qC; 1H NMR (400 MHz, 
CDCl3į+V+V+V+V+V+V
(1H, dd, J = 8.0, 2.0 Hz), 6.83-6.88 (2H, m), 7.03-7.08 (2H, m), 7.23-7.29 (3H, m), 7.78 (1H, 
s); 13C NMR (101 MHz, CDCl3į56.1, 56.2, 56.3, 61.1, 105.9, 110.5, 115.0, 120.7, 121.0, 
127.0, 128.1, 128.3, 129.0, 129.1, 136.5, 136.9, 145.5, 146.4, 148.5, 153.2 (one sp2 carbon 
not observed); )7,5Ȟmax  2929 (br), 1584 (m), 1520 (m), 1374 (m), 1246 (m), 1120 (s), 1007 
(m); HRMS (ESI-TOF) m/z [M+H]+ calculated for C26H26N2O5: 447.1914. Found: 447.1914; 
HPLC: Ret. Time: 16.07 min, Purity 98.6%. 
4-(3,4,5-Trimethoxyphenyl)-5-(3-hydroxy-4-methoxyphenyl)-pyrazole (31). A solution of 
pyrazole 40 (274 mg, 0.614 mmol)  in methanol (6 mL) and AcOH (6 drops) was flowed 
through a H-Cube continuous flow hydrogenator (1 mL miní1 ) with a 10% Pd/C catalyst 
cartridge at 80 °C using controlled H2 mode (80 bar) as a continuous loop. Once the reaction 
was complete by TLC analysis, the system was washed with methanol (10 mL). The reaction 
was subsequently neutralized with NaHCO3 then filtered and the volatiles were removed in 
vacuo. Flash silica chromatography (gradient starting with 100% 40-60 petroleum ether and 
ending with 100% ethyl acetate in 40-60 petroleum ether) afforded pyrazole 31 as a 
colourless solid (144 mg, 66%). See above for characterization. 
1-(Methyl)-3-(3,4,5-trimethoxyphenyl)-pyrazole (33). N-Methylsydnone (150 mg, 1.50 
mmol) and 3,4,5-trimethoxyphenylacetylene (576 mg, 3.00 mmol) were subjected to general 
procedure B,  affording pyrazole 33 as an orange oil (236 mg, 63%, >98:2). 1H NMR (400 
MHz, CDCl3į+V+V),  6.45 (1H, d, J = 2.0 Hz), 6.99 (2H, s), 7.33 (1H, d, 
J = 2.0 Hz); 13C NMR (101 MHz, CDCl3 į  56.1, 60.9, 102.6, 102.7, 129.4, 131.5, 
137.6, 151.4, 153.4; )7,5Ȟmax  2930 (w), 2827 (w), 1588 (m), 1507 (m), 1401 (m), 1232 (s), 
1127 (s), 1008 (m); HRMS (ESI-TOF) m/z [M+H]+ calculated for C13H17N2O3: 249.1234. 
Found: 249.1230. 
1-(Benzyl)-3-(3,4,5-trimethoxyphenyl)-pyrazole (34a, major) and 1-(benzyl)-4-(3,4,5-
trimethoxyphenyl)-pyrazole (34b, minor). N-Benzylsydnone (200 mg, 1.14 mmol) and 
3,4,5-trimethoxyphenylacetylene (436 mg, 2.27 mmol) were subjected to general procedure 
B,  affording an inseparable mixture of pyrazoles 34a and 34b as an orange oil (239 mg, 
64%, 9:1). 1H NMR (400 MHz, CDCl3į+V+V+V+
d, J = 2.5 Hz), 7.05 (2H, s), 7.21-7.28 (2H, m), 7.29-7.40 (4H, m); 13C NMR (101 MHz, 
CDCl3 į            
151.6, 153.6; )7,5Ȟmax  2934 (w), 1587 (m), 1500 (m), 1423 (m), 1228 (s), 1125 (s), 1000 
(s); HRMS (ESI-TOF) m/z [M+H]+ calculated for C19H21N2O3: 325.1547. Found: 325.1550. 
1-(Methyl)-3-([3-tert-butyldimethyloxy]-4-methoxyphenyl)-pyrazole (35a, major) and 1-
(methyl)-4-([3-tert-butyldimethyloxy]-4-methoxyphenyl)-pyrazole (35b, minor). N-
Methylsydnone (163 mg, 1.63 mmol) and (3-tert-butyldimethyloxy)-4-
methoxyphenylacetylene (787 mg, 3.00 mmol) were subjected to general procedure B, 
affording an inseparable mixture of pyrazole 35a and 35b was isolated as an orange oil (339 
mg, 65%, 9:1). 1H NMR (400 MHz, CDCl3į+s), 1.01 (9H, s), 3.82 (3H, s), 3.93 
(3H, s),  6.43 (1H, d, J = 2.5 Hz), 6.86 (1H, d, J = 8.5 Hz), 7.29 (1H, d, J = 2.0 Hz), 7.32-7.36 
(2H, m); 13C NMR (101 MHz, CDCl3 į -4.5, 18.6, 25.9, 39.1, 55.6, 102.5, 112.2, 118.6, 
119.1, 126.9, 131.3, 145.2, 150.8, 151.6; )7,5Ȟmax  2952 (w), 2930 (w), 2857 (w), 1508 (m), 
1472 (m), 1271 (s), 1229 (s), 1135 (m), 992 (m), 915 (s); HRMS (ESI-TOF) m/z [M+H]+ 
calculated for C17H27N2O2Si: 319.1836. Found: 319.1832. 
1-(Benzyl)-3-([3-tert-butyldimethyloxy]-4-methoxyphenyl)-pyrazole (36a, major) and 1-
(benzyl)-4-([3-tert-butyldimethyloxy]-4-methoxyphenyl)-pyrazole (36b, minor). N-
Benzylsydnone (200 mg, 1.14 mmol) and (3-tert-butyldimethyloxy)-4-
methoxyphenylacetylene (598 mg, 2.28 mmol) were subjected to general procedure B, 
affording an inseparable mixture of pyrazoles 36a and 36b as an orange oil (263 mg, 58%, 
>98:2). 1H NMR (400 MHz, CDCl3į+V+V+V+V),  
6.49 (1H, d, J = 2.5 Hz), 6.89 (1H, d, J = 8.5 Hz), 7.24-7.28 (2H, m), 7.31-7.38 (5H, m), 7.42 
(1H, dd, J = 8.5, 2.0 Hz); 13C NMR (101 MHz, CDCl3į-4.5, 18.6, 25.9, 55.6, 56.1, 103.0, 
112.2, 118.7, 119.2, 126.9, 127.8, 128.0, 128.8, 130.5, 136.8, 145.2, 150.8, 151.4; )7,5Ȟmax  
2952 (w), 2929 (w), 2857 (w), 1504 (m), 1472 (m), 1271 (s), 1229 (s), 1134 (m), 995 (m), 
915 (m); HRMS (ESI-TOF) m/z [M+H]+ calculated for C23H31N2O2Si: 395.2149. Found: 
395.2147.  
1-(Methyl)-3-(3,4,5-trimethoxyphenyl)-4-(3-hydroxy-4-methoxyphenyl)-pyrazole (37). 
Pyrazole 33 (543 mg, 2.19 mmol), NBS (389 mg, 2.19 mmol), 3-hydroxy-4-
methoxyphenylboronic acid pinacol ester (822 mg, 3.29 mmol), XPhosPdG2 (172 mg, 0.219 
mmol) and Na2CO3 (812 mg, 7.67 mmol) were subjected to general procedure Fi,  affording 
pyrazole 37 as a tan solid (551 mg, 68%). The product could be further purified by 
recrystallization from pentane. M.p.: 46-48 qC; 1H NMR (400 MHz, CDCl3į (6H, s), 
3.72 (3H, s), 3.83 (3H, s),  3.95 (3H, s), 5.85 (1H, s), 6.74-6.77 (3H, m), 6.82 (1H, dd, J = 
8.0, 2.0 Hz), 6.86 (1H, d, J = 8.0 Hz), 7.40 (1H, s); 13C NMR (101 MHz, CDCl3į
56.0, 61.0, 106.3, 111.9, 114.5, 120.8, 121.9, 125.4, 129.1, 130.2, 137.5, 144.7, 146.5, 148.3, 
153.0; )7,5Ȟmax  3405 (br), 2935 (w), 2831 (w), 1587 (m), 1556 (m), 1508 (m), 1462 (m), 
1413 (s), 1234 (s), 1119 (s), 1002 (m); HRMS (ESI-TOF) m/z [M+H]+ calculated for 
C20H23N2O5: 371.1601. Found: 371.1602; HPLC: Ret. Time: 12.82 min, Purity 95.2%. 
1-(Benzyl)-3-(3,4,5-trimethoxyphenyl)-4-(3-hydroxy-4-methoxyphenyl)-pyrazole (38). 
Pyrazoles 34a and 34b (398 mg, 1.23 mmol, 9:1), NBS (218 mg, 1.23 mmol), 3-hydroxy-4-
methoxyphenylboronic acid pinacol ester (461 mg, 1.85 mmol), XPhosPdG2 (97 mg, 0.123 
mmol) and Na2CO3 (456 mg, 4.31 mmol) were subjected to general procedure Fi, affording 
pyrazole 38 as a colourless solid (323 mg, 59%). The product could be further purified by 
recrystallization from ethyl acetate/40-60 petroleum ether. M.p.: 168-169 qC; 1H NMR (400 
MHz, CDCl3į (6H, s), 3.72 (3H, s), 3.84 (3H, s),  5.36 (2H, s), 5.64 (1H, s), 6.74 (1H, 
d, J = 2.0 Hz), 6.79 (2H, s), 6.82 (1H, dd, J = 8.0, 2.0 Hz), 6.86 (1H, d, J = 8.0 Hz), 7.31-7.42 
(5H, m), 7.38 (1H, s); 13C NMR (101 MHz, CDCl3į111.8, 
114.5, 121.2, 122.0, 125.4, 128.1, 128.3, 129.0, 129.2 (x2 C), 136.4, 137.6, 144.7, 146.4, 
148.3, 153.1; )7,5Ȟmax  2957 (w), 2933 (w), 1588 (m), 1558 (m), 1507 (m), 1418 (m), 1265 
(m), 1240 (m), 1116 (s), 1004 (m); HRMS (ESI-TOF) m/z [M+H]+ calculated for 
C26H27N2O5: 447.1914. Found: 447.1913; HPLC: Ret. Time: 16.29 min, Purity 95.8%. 
1-(Methyl)-3-(3-hydroxy-4-methoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-pyrazole (39). 
Pyrazoles 35a and 35b (125 mg, 0.392 mmol), NBS (70 mg, 0.392 mmol), potassium 3,4,5-
trimethoxyphenyltrifluoroborate (159 mg, 0.580 mmol), XPhosPdG2 (31 mg, 0.039 mmol) 
and Na2CO3 (83 mg, 0.784 mmol) and K2CO3 (163 mg, 1.18 mmol) were to general 
procedure Fii, affording pyrazole 39 as a colourless solid (63 mg, 43%). The product could be 
further purified by recrystallization from ethyl acetate/40-60 petroleum ether. M.p.: 171 qC; 
1H NMR (400 MHz, CDCl3į (6H, s), 3.86 (3H, s), 3.88 (3H, s),  3.95 (3H, s), 5.62 (1H, 
s), 6.50 (2H, s), 6.79 (1H, d, J = 8.5 Hz), 7.00 (1H, dd, J = 8.5, 2.0 Hz), 7.15 (1H, d, J = 2.0 
Hz), 7.44 (1H, s); 13C NMR (101 MHz, CDCl3į
120.6 (x2 C), 127.0, 129.0, 130.0, 136.9, 145.5, 146.4, 148.5, 153.2; )7,5Ȟmax  3122 (br), 
2965 (w), 2934 (w), 2838 (w), 1585 (m), 1462 (m), 1411 (s), 1338 (m), 1228 (s), 1127 (s), 
1016 (m), 1000 (m); HRMS (ESI-TOF) m/z [M+H]+ calculated for C20H23N2O5: 371.1601. 
Found: 371.1598; HPLC: Ret. Time: 13.49 min, Purity 95.3%.  
1-(Benzyl)-3-(3-hydroxy-4-methoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-pyrazole (40). 
Pyrazoles 36a and 36b (252 mg, 0.639 mmol), NBS (114 mg, 0.639 mmol), potassium 3,4,5-
trimethoxyphenyltrifluoroborate (263 mg, 0.959 mmol), XPhosPdG2 (50 mg, 0.064 mmol) 
and Na2CO3 (135 mg, 1.28 mmol) and K2CO3 (265 mg, 1.92 mmol) were subjected to general 
procedure Fii, affording pyrazole 40 as a colourless solid (93 mg, 33%). The product could be 
further purified by recrystallization from ethyl acetate/40-60 petroleum ether. M.p.: 56-58 qC; 
1H NMR (400 MHz, CDCl3į+V+V+V),  5.35 (2H, s), 5.54 (1H, 
s), 6.48 (2H, s), 6.80 (1H, d, J = 8.5 Hz), 7.02 (1H, dd, J = 8.5, 2.0 Hz), 7.19 (1H, d, J = 2.0 
Hz), 7.30-7.40 (5H, m), 7.41 (1H, s); 13C NMR (101 MHz, CDCl3į
105.9, 110.5, 115.0, 120.7, 121.0, 128.1, 128.3, 129.0, 129.1, 136.5, 136.9, 145.5, 146.4, 
148.5, 153.2 (two sp2 carbons not observed); )7,5Ȟmax  2935 (w), 1583 (m), 1455 (m), 1406 
(m), 1234 (s), 1122 (s), 1001 (m); HRMS (ESI-TOF) m/z [M+H]+ calculated for C26H27N2O5: 
447.1914. Found: 447.1914; HPLC: Ret. Time: 16.34 min, Purity 97.0%.  
Endothelial cell culture. Human Umbilical Vein Endothelial Cells (HUVECs) from pooled 
donors (Promocell, C-12203) were cultured on gelatin-coated dishes in endothelial cell basal 
medium (EBM) (Promocell: C-22010) supplemented with Endothelial Cell Growth 
Supplement Mix (Promocell: C-39215). The supplemented medium contained 2% foetal calf 
serum (FCS), 0.4% Endothelial Cell Growth Supplement (ECGS), 0.1 ng/ml recombinant 
Human Epidermal Growth factor (hEGF), 1 ng/ml recombinant human Basic Fibroblast 
Growth Factor (hbFGF), 90 µg/ml heparin and 1 µg/ml hydrocortisone. Further low 
endotoxin heat inactivated FCS was then added to the medium to increase the final 
concentration to 10% (v/v). Cells were then kept at 37°C in a humidified incubator, were sub-
cultured by trypsinisation when confluent and were used for up to 5 passages. 
Immunofluorescence staining of the cell cytoskeleton. Immunofluorescence staining was 
used to visualize changes in cell morphology and the cytoskeleton. HUVECs were plated on 
4 or 8 well fibronectin-coated Permanox chamber slides at 2.5 x 104 cells per well in 250 µl 
EBM for 8 well slides and 5 x 104 cells per well in 500 µl for 4 well slides.. Microtubules and 
actin filaments were stained according to general staining protocols described previously.40  
For activity studies, various concentrations of each drug were prepared in EBM via 
systematic dilutions from a 20 mM stock in DMSO. The cells were treated with drug or 
vehicle control for 30 minutes. The media were then discarded and the cells fixed with 3.7% 
formalin in PBS for 10-20 minutes, and permeabilized in 0.1% triton X-100 prior to staining 
the cytoskeleton. 
For recovery studies, cells were treated with drug or vehicle control for 30 or 60 minutes at 
37 °C The medium was then removed and cells were washed four times with fresh medium 
containing serum. The cells were then placed in the incubator for 30 minutes; the washing 
procedure was then repeated and the cells incubated for a further 30 minutes.  
Cell Proliferation Studies. The effects of various drugs on cell proliferation were 
established and GI50 values were obtained.  96-multiwell plates were coated with 0.2% 
gelatin in PBS for at least 30 minutes prior to culture. Cells were plated at 5 x 103/well in 100 
µl medium and left to adhere for 24 hours. Different concentrations of drugs were then added 
in 50 µl of EBM. A minimum of 8 wells were used for each drug concentration or vehicle 
control. The cells were incubated at 37 °C for 72 hours before the media were removed and 
cells were fixed with 3.7% formalin for 10-20 minutes. The wells were then washed four 
times with PBS and stained with 1% crystal violet (Sigma, Cat: C3886) solution in 10% 
ethanol for 10-20 minutes at room temperature. The plates were then repeatedly rinsed with 
water, dried overnight and then stained cells were lysed in 100 µl of 10% acetic acid. The 
absorbance at 590 nm was then recorded by a plate reader. The absorbance data was 
corrected against background (empty wells with lysis solution) and transformed into 
percentage growth inhibition for each drug concentration. Percentage growth inhibition 
values obtained from at least 3 independent experiments were plotted against the logarithm of 
drug concentration using GraphPad Prism software and GI50 values were established for each 
drug.  
 
Endothelial Monolayer Permeability Assay. Cell culture inserts (Falcon: 353492) with a 
PET track etched membrane with pore size of 3 Pm (2.0 ± 0.2 x 105 pores/cm2) were coated 
(5 Pg/mL) fibronectin for a minimum of 30 minutes. Cells were then plated at 5.0 x 104 cells 
per insert in 200 µl EBM. Each insert was placed in a well of a 24-multiwell companion 
plate, (Falcon: 353504) and 700 PL of EBM were added to the lower well. In each 
experiment 200 µl EBM without cells were added to one insert coated with fibronectin.  The 
cells were kept at 37°C in a humidified incubator for 24 hours before the media were changed 
in both the wells and inserts. The cells were then kept at 37°C in a humidified incubator for a 
further 4 days. The cells were treated by the direct addition of 25 PL of drug solution into the 
insert and incubated at 37°C for 30 minutes. The media were removed from the inserts and 
replaced with 200 PL EBM containing FITC-dextran (0.8 mg/mL) (Sigma: 46945). Inserts 
were then placed into the wells of a new 24-multiwell plate containing 700 PL of EBM and 
incubated at 37 °C in a humidified incubator for 30 minutes. Samples of media were taken 
from the lower well compartments and fluorescence was quantified on a plate reader at 
excitation 488, emission 525. The raw emission reading from each well was transformed into 
% emission relative to the well without cells, which was normalized to 100% emission 
(equivalent to 100% permeability). The perturbation of the monolayer was proportional to the 
emission of FITC-dextran that passed through the insert into the well. 
Analysis of pMLC phosphorylation by Western Blotting. HUVECs were cultured in 
gelatin-coated 12-multiwell plates at at 5 x 104 cells per well in 1 mL EBM and kept at 37 °C 
in a humidified incubator for 7 days without media changes. Various concentrations of drugs 
were prepared in EBM via systematic dilutions from a 20 mM stock in DMSO except for Rho 
kinase inhibitor Y-27632 (Tocris), which was prepared as a 20 mM stock solution in dH2O 
and used at a final concentration of 5 PM. Following drug exposure, cell culture media were 
discarded and proteins were extracted in 1 x NuPAGE LDS reducing sample buffer (LDS, 
ThermoFisher, Cat.: NP0008). The samples were then analyzed for MLC phosphorylation by 
western blotting using an antibody to dually phosphorylated MLC (Cell Signalling, ݡ3674) 
as described previously.40 Blots were stripped and reprobed using an antibody to actin 
(Sigma, Cat.:A4700). 
In Vivo Analysis and Necrosis Scoring. All animal care and experimental procedures were 
carried out in accordance with the UK Animals (Scientific Procedure) Act 1986, with local 
ethics committee approval and following published guidelines for the use of animals in 
cancer research.44 Human colorectal adenocarcinoma SW1222 cells were injected s.c. (5 × 
106 cells in 0.05 mL) into the rear dorsum of female severe combined immunodeficiency 
(SCID) mice (8±12 weeks old, 20±25 g). Three orthogonal diameters of subcutaneous tumors 
were measured using calipers and tumors were treated when they reached approximately 8 
mm in mean diameter. Vehicle (50% Na2CO3/NaCl, 10 mL/kg), CA4P (100 mg/kg, 0.227 
mmol/kg, in 50% Na2CO3/NaCl, 10 mL/kg) or a solution of 31 (81 mg/kg, 0.227 mmol/kg, 
50% Na2CO3/NaCl, 10 mL/kg), was given as a single dose. Subcutaneous tumors were 
formalin-fixed, paraffin-embedded, and hematoxylin and eosin (H & E) stained 24 hours after 
treatment. The percentage of necrosis was measured from H&E sections and quantified 
according to a random points scoring (Chalkley) system.42,43 
Statistics. Statistical analysis was carried out using GraphPad Prism 6 for Windows 8.1. The 
significance of differences between groups was assessed using a one-way ANOVA followed 
by a Tukey post-test, with p<0.05 considered significant. 
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